UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

International journal of gynecological cancer, 2022-06, Vol.32 (6), p.761-768

2022

Link zum Volltext

Verfügbarkeit prüfen

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study

The oncologist (Dayton, Ohio), 2017-09, Vol.22 (9), p.1117-1124

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Patient related outcome measures, 2023-05, Vol.14, p.111-126

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS5077-TPS5077

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS5078-TPS5078

2015

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5547-5547

2015

Link zum Volltext

Verfügbarkeit prüfen

Convenors' Welcome

Asia-Pacific journal of clinical oncology, 2021-08, Vol.17 (S4), p.6-6

2021

Link zum Volltext

Verfügbarkeit prüfen

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Cochrane database of systematic reviews, 2019-10, Vol.10 (10), p.CD012160-CD012160

2019

Link zum Volltext

Verfügbarkeit prüfen

Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors

Clinical genitourinary cancer, 2024-08, Vol.22 (4), p.102116, Article 102116

2024

Link zum Volltext

Verfügbarkeit prüfen

Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

Gynecologic oncology, 2024-06, Vol.185, p.128-137

2024

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14576-e14576

2019

Link zum Volltext

Verfügbarkeit prüfen

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS396-TPS396

2023

Link zum Volltext

Verfügbarkeit prüfen

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4537-4537

2022

Link zum Volltext

Verfügbarkeit prüfen

How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC)

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.5549-5549

2019

Link zum Volltext

Verfügbarkeit prüfen

Patients' perception of the benefits of palliative systemic therapy for advanced cancer

Internal medicine journal, 2024-05, Vol.54 (5), p.735-741

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS261-TPS261

2020

Link zum Volltext

Verfügbarkeit prüfen

UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.325-325

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaAntineoplastic Combined Chemotherapy Protocols - Therapeutic Use

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(28)
Tagungsberichte
(4)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Medicin Och Hälsovetenskap
(9)
Oncology
(8)
Obstetrics & Gynecology
(4)
Adult
(3)
Humans
(3)
Quality Of Life
(3)
Aged
(2)
Aged, 80 And Over
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Cancer
(2)
Female
(2)
General & Internal Medicine
(2)
Medicine, General & Internal
(2)
Middle Aged
(2)
Ovarian Cancer
(2)
Prognosis
(2)
Recurrent Ovarian Cancer
(2)
Urology & Nephrology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304)

Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303)

Development and validation of a prognostic nomogram to predict overall survival (OS) in platinum-resistant ovarian cancer (PROC): An AURELIA substudy

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)

Convenors' Welcome

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Adherence Outcomes and Risk Factors Predicting Nonadherence to Active Surveillance in Patients With Stage 1 Testicular Germ Cell Tumors

Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer

Characteristics of preceding trials associated with the outcome of subsequent phase III (P3) trials of targeted and immunological therapies in advanced cancers

DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Sequential immunotherapy in rare variant renal cell carcinomafinal report of UNISoN (ANZUP 1602): Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma

How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC)

Patients' perception of the benefits of palliative systemic therapy for advanced cancer

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma

UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1—Nivolumab monotherapy

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

Aktive Filter

Suchergebnisse filtern